Aevi Genomic Medicine Reports Second Quarter 2017 Financial Results

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share data)

Six months endedJune 30,

Three months endedJune 30,

2017

2016

2017

2016

Unaudited

Unaudited

Research and development expenses

$      13,614

$     15,692

$        5,667

$       8,741

General and administrative expenses

5,357

7,136

2,369

2,945

Operating loss

(18,971)

(22,828)

(8,036)

(11,686)

Financial income / (expense)

21

(20)

3

(18)

Loss before taxes on income

(18,950)

(22,848)

(8,033)

(11,704)

Taxes on income

-

3

-

3

Net loss

$     (18,950)

$    (22,851)

$       (8,033)

$    (11,707)

Basic and diluted loss per share

$         (0.51)

$        (0.69)

$         (0.22)

$        (0.35)

Weighted average number of common stock used incomputing basic loss per share

37,109,157

33,211,665

37,110,043

33,469,789